Tag: Histogen Inc. (NASDAQ: HSTO)


Histogen Inc. (NASDAQ: HSTO) Jumps 16% After Releasing Promising Phase 1 Emricasan Study Results in COVID-19

Histogen Inc. (NASDAQ: HSTO) jumped 16.16% after the company and Amerimune LLC, its partner, announced the top-line resulted from the phase 1 study assessing emricasan’s safety, preliminary efficacy, and tolerability in the treatment of patients with mild symptomatic COVID-19.  Emricasan shows favorable safety and tolerability profile.  Compared to placebo, emricasan […]